Here comes a new emerging company in Biotechnology! Holy Stone Healthcare Co., Ltd. will be listed on Taiwan’s emerging stock market, at NT$58.00 per share, on December 13, 2013. Expected time to be listed on the IPO stock market will be within the following six months.
 
Holy Stone Healthcare Co., Ltd. was founded in 2001 with a capital of NT$6.06 hundred million. The current President is Mr. Jing-Rong Tang.
 
International pharmaceutical companies hope to invest fewer and obtain larger reward. Through the strategy of "drug delivery system" to maintain product's life cycle and provide better results for patients or after clinical treatments. This has proven to be the most effective way.
 
The development of bio-polymer drug delivery platform, based on "hyaluronic acid drug delivery technology platform", has six patents. These include indication of hyaluronic acid application, and establishment of a complete patent portfolio on compositions, prescriptions, and dosage forms. Holy Stone is also collaborating resources from domestic and foreign academic institutions and clinical medical centers to develop a number of techniques and formulations, and utilizing these techniques and formulations in the development of new medical devices and drugs such as those for breast cancer (epithelial cells), colorectal cancer, lung cancer and acute leukocyte cancer” said by prolocutor of Holy Stone Healthcare Co., Ltd .
 
With Hyaluronic acid as a drug delivery platform, Holy Stone Healthcare has developed a new drug, IBD98-M, for the treatment of inflammatory bowel disease. IBD98-M is expected to be applied for the U.S. FDA drug review through 505 (b) (2), greatly lowering the review time for listing. And the new drug is expected to start the U.S. IND PhaseⅠtest in Q1 of 2014. Moreover, within this year and the next, there are a number of new medical devices for intestinal diseases treatment using hyaluronic acid. This not only adds business momentum, but also shows the significant potential of "hyaluronic acid drug delivery technology platform.